Valchlor in the Treatment of Lichen Planopilaris

• Status: Completed
• Trial end date: 2019-08-30
• Target enrollment: 0
• Participant gender: All

Summary

The primary objective of this study is to assess the potential effectiveness of once daily application of Valchlor in decreasing disease activity in patients with Lichen Planopilaris. The primary measurement of efficacy will be with the Lichen Planopilaris Activity Index (LPPAI) before and after 6 months of treatment. Secondary measures of efficacy will be the mean follicular density, Physician Global assessment (PGA) score, and the Dermatology Quality of Life Index (DQLI) score before and after six months of therapy.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Mayo Clinic
• Collaborator: Actelion
• Treatments: Mechlorethamine

Criteria

Inclusion Criteria:

• Male and female patients 18 years or older.

• Biopsy proven diagnosis of Lichen Planopilaris

• Biopsy proven diagnosis of Fontal Fibrosing Alopecia (a clinical variant of LPP restricted to frontal scalp)

• Good general health as confirmed by medical history

• Patients who are willing and capable of cooperating to the extent and degree required by the protocol; and

• Patients who read and sign an approved informed consent for this study

Exclusion Criteria:

• Vulnerable study population

• Pregnant or nursing women

• Women planning a pregnancy within the study period

• Active smokers

• Known history of adverse reaction to mechlorethamine

• Use of systemic immunosuppressive

• Presence of ulcerated scalp lesions